Sponsors

Sponsor the Meeting

cell-icon-hiresInterested in gaining extensive marketing exposure and access to the advanced therapies industry? Contact Laura Parsons at lparsons@alliancerm.org for full sponsorship information for the 2015 Stem Cell Meeting on the Mesa.

Gold Sponsors

BioLife_210_websiteBioLife Solutions develops, manufactures and markets biopreservation media and high performance thermal packaging products for cells, tissues and organs. The Company’s proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery and regenerative medicine markets. BioLife’s products are serum-free and protein-free, fully defined and are formulated to reduce preservation-induced cell damage and death.  BioLife’s enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues and organs. www.biolifesolutions.com

Mesoblast_210_websiteMesoblast Limited is developing novel biotherapeutics derived from its proprietary adult stem cell-based technologies. The Company’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat a broad range of conditions with major unmet medical needs. Its strategic product development focus is in four major and distinct areas – systemic inflammatory conditions, cardiovascular diseases, orthopedic diseases of the spine and oncology conditions. Mesoblast’s corporate strategy is to leverage proprietary cell-based and complementary biologic technologies to develop products for unmet medical needs; bring multiple products to market within a parallel timeframe; underpin future financial growth through investing in manufacturing operations; and enhance the likelihood of commercial success through strategic partnerships. Mesoblast’s strong cash reserves ($315M) enable simultaneous product development with future revenues expected from milestone payments, distribution arrangements and direct sales. www.mesoblast.com

MiMedx_180MiMedx® is the premier processor of regenerative biomaterial products and implants from human amniotic membrane. MiMedx has distributed hundreds of thousands of amniotic tissue grafts worldwide. Profound clinical outcomes have been achieved in therapeutic areas including ophthalmology, spine, wounds, dental, orthopedic, surgery, sports medicine and urology. With this innovative allograft that promotes bioactive healing, MiMedx® believes its intellectual property and proprietary processing technique strategically positions the Company as the leader in this area of regenerative medicine. www.mimedx.com

PCT_180_websiteProgenitor Cell Therapy (PCT) is an internationally recognized client-oriented service company, with a long-term commitment to the development, manufacturing and commercialization of cell therapies. PCT offers cost-effective turnkey service solutions for consulting and regulatory support, GLP/GTP/cGMP-compliant product development and manufacturing services, storage, distribution and logistics support, with the goal of establishing tailor-made service platforms providing the core benefits of operational leverage and control, financial value and risk mitigation. www.pctcelltherapy.com

Sangamo_120Sangamo BioSciences is a clinical-stage gene therapy company focused on Engineering Genetic Cures™ for monogenic and infectious diseases.  Sangamo is dedicated to the development of novel ZFP Therapeutics® using its proprietary zinc finger DNA-binding protein (ZFP) technology platform.  The Company has an ongoing Phase II clinical trial to evaluate the safety and efficacy of a novel T-cell based ZFP Therapeutic® for the treatment of HIV/AIDS. This application is being expanded into hematopoietic stem cells to enable the genetic engineering of an HIV-resistant immune system. The Company intends to file an IND application for this program in 2014. Sangamo’s other therapeutic programs are focused on stem cell applications in monogenic diseases such as hemoglobinopathies, including sickle cell disease and beta-thalassemia, and additional monogenic indications including hemophilia A and B, lysosomal storage disorders and Huntington’s disease. www.sangamo.com

SDI_210_websiteScottish Development International (SDI) is Scotland’s agency for economic development. Scotland’s stem cell and regenerative medicine cluster delivers a ”one-stop” solution for companies developing applications at preclinical, clinical or commercial stages of development. This dynamic commercial and academic landscape provides unique solutions across the whole supply chain including cell line supplies, screening, characterization, GMP manufacturing, QA/QC and a range of enabling technologies and other supporting services. Scotland has a proven track record in implementing cell therapy clinical trials using the world-class MHRA-accredited GMP ATMP manufacturing facilities for Phase I and II embryonic and adult stem cells. All of this expertise is in close proximity across Scotland with excellent connections to the rest of Europe. This makes Scotland the ideal location for academic research collaborations, stem cell technology research and development, clinical/translational research and cell line manufacturing. www.sdi.co.uk

Silver Sponsors

CCRM_140The Centre for Commercialization of Regenerative Medicine (CCRM) is a Canadian not-for-profit, public-private consortium funded by the Government of Canada’s Networks of Centres of Excellence program, six Ontario-based institutional partners and more than 30 companies representing the key sectors of the regenerative medicine industry. CCRM supports the development of technologies that accelerate the commercialization of stem cell- and biomaterials-based technologies and therapies. The office, located at the Banting Institute at the University of Toronto, has a 6,000 square foot development facility that houses three platforms: Cell Reprogramming and Engineering; Cell Manufacturing; and, Biomaterials and Devices. A network of academics, industry and entrepreneurs, CCRM translates scientific discoveries into marketable products for patients. CCRM launched in Toronto’s Discovery District on June 14, 2011. www.ccrm.ca

CellGenix_170_websiteCellGenix manufactures GMP reagents for ex-vivo cell culture of DC’s, T-Cells, NK-Cells, HSC’s and MSC’s. We follow strict guidelines to ensure reliability, safety and reproducible results for preclinical and clinical applications. CellGenix products are used in clinical centers worldwide in cancer and regenerative medicine. www.cellgenix.com

Fresenius-Kabi_140Fresenius Kabi is a global healthcare company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. Our products and services are used to help care for critically and chronically ill patients. Everything we do at Fresenius Kabi has one ultimate purpose: to put lifesaving medicines and technologies in the hands of people who care for patients, and to find answers to the challenges they face. Fresenius Kabi is pleased to now offer the Fenwal portfolio of transfusion technologies including the Amicus therapeutic apheresis and cell collection platform for therapeutic plasma exchange (TPE) and MNC collection. www.fresenius-kabi.us

Lonza_135_websiteLonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. www.lonza.com

Medpace_170_websiteMedpace is a global full-service Clinical Research Organization (CRO) providing comprehensive development services for drug, biologic and device programs. Medpace has strong experience supporting development programs for regenerative medicine products across a number of therapeutic areas including cardiovascular, neuroscience, musculoskeletal and diabetes. With extensive medical expertise, a renowned regulatory affairs department and direct global operations in over 40 countries, Medpace conducts studies and navigates regulatory requirements worldwide. From feasibility, research site compatibility, safety and logistics, Medpace brings efficiencies and operational excellence to regenerative medicine development programs. In addition, Medpace offers integrated imaging and lab capabilities through its family of companies to provide cohesive, streamlined and standardized trial management. www.medpace.com

StemBioSys_190_websiteStemBioSys, based in San Antonio, Texas, is a privately-held biomedical company focused on the isolation, growth and delivery of adult stem cells for clinical use. Its patented and proprietary technology platforms – licensed from the University of Texas Board of Regents – overcome key obstacles to creating clinically useful stem cell therapies. The centerpiece of these enabling technologies is the HPMETM (High Performance Micro Environment™) platform. This cell derived three-dimensional microenvironment allows a variety of stem cells to replicate more rapidly and with greater preservation of stem cell properties compared to more traditional tissue culture substrates. This disruptive technology is positioned to transform and improve the methods and cost of isolating, growing and delivering various stem cell populations for applications in research, therapeutic applications and drug discovery. We are currently ramping up GMP production of the core HPME product in preparation for proof of concept testing in various applications. www.stembiosys.com

Terumo_190_websiteTerumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers. www.terumobct.com

Bronze Sponsors

Celgene_65Since its beginnings, Celgene has experienced tremendous growth and geographic expansion. The Celgene of today is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives, reducing the burden on healthcare systems and helping economies grow. Today, Celgene employs world-class biopharmaceutical talent across the globe, and for all of its growth and expansion, Celgene remains true to its DNA – a genetic heritage based on a promise that runs from generation to generation. A promise to support, nurture and create medical innovation, to think differently, to disrupt, to be bold, to be agile and to persevere. It is a promise to change the course of human health while always putting patients first. www.celgene.com

Cognate_110_websiteCognate Bioservices is a fully-integrated contract bioservices organization providing the highest level of scientific and management expertise. Cognate provides full development and cGMP manufacturing services to companies and institutions engaged in the development of cell-based products. The combination of highly experienced staff, cGMP facilities and international track record makes Cognate one of the most experienced contract manufacturers of cell based products in the world today. www.cognatebioservices.com

CTI_130_websiteCTI Clinical Trial & Consulting Services is an innovative, international drug and device development organization that delivers a full spectrum of clinical trial and consulting services from bench to commercialization, with a focus on immunology and a passion for helping life-changing therapies succeed in chronically and critically ill patient populations. CTI’s focused therapeutic approach provides pharmaceutical, biotechnology and startup firms with clinical and disease area expertise from a unique mix of academic, medical and industry specialists; rich intellectual capital in solid organ and stem cell transplantation, immunology, infectious disease, hematology, regenerative medicine and rare diseases; flexible study designs that accelerate development programs and deliver high approval ratings that are among the best in the industry; and exceptional global project management and gold standard safety and data management systems that strengthen their program’s success potential. Established in 1999 and headquartered in Cincinnati, Ohio, CTI has offices in North America, Europe and South America. www.ctifacts.com

EBD_60_websiteEBD Group is the leading partnering firm for the global life science industry. Since 1993, biotech, pharma and medical device companies have leveraged EBD Group’s partnering conferences, technology and services to identify and develop strategic relationships. 
Our conferences, run with the support of leading corporations and international trade associations, include BIO-Europe®, BIO-Europe Spring®, BioPharm America™, EuroMedtech™, BioEquity Europe, ChinaBio® Partnering Forum, The Global Impact Forum™ and Biotech Showcase™.
 EBD Group’s sophisticated web-based partnering service, partneringONE®, also powers numerous third-party events, and partnering360® is the online community of life science executives that enhances dealmaking productivity year round. www.ebdgroup.com

Histogenics_125_websiteHistogenics was incorporated in 2000 with an initial focus of developing products that meaningfully improve the lives of patients with defects in cartilage and joints. In May 2011, the Company acquired ProChon Biotech, a privately-owned biotechnology company based in Israel, which enabled a synthesis of products, technology and materials science by establishing a robust scientific and technology platform targeting tissue repair solutions. Histogenics’ goal is to become a leading regenerative medicine company developing, marketing and commercializing products in the musculoskeletal segment of the marketplace. The Company is building its core technology platform and plans to expand its clinical products’ therapeutic applications to develop new and innovative solutions for musculoskeletal conditions. Histogenics leverages a combination of the latest advances in molecular biology and proprietary materials sciences to create products designed to help improve patient outcomes. www.histogenics.com

TiGenix_110_websiteTiGenix, founded in the year 2000 to clinically develop and bring to market novel cell therapeutic products, is the only European cell therapy company that benefits from the combination of top-line sales (through its marketed product ChondroCelect) and long term growth potential through its pipeline of adipose-derived stem cell products. TiGenix’s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASCs) targeting autoimmune and inflammatory diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the EMA. Its lead candidate is Cx601, currently finalizing the recruitment of a single pivotal Phase III in Europe for complex perianal fistulas in Crohn’s patients. The results are expected Q3 2015 and filing for approval in Europe in the first half of 2016. After a successful end of Phase II meeting with the FDA, the Company will file for an SPA before the end of 2014 for the second pivotal trial that will allow for a BLA filing. TiGenix announced recently the clinical development of Cx611, its intravenous-administered allogeneic stem cell product, in early rheumatoid arthritis and severe sepsis. www.tigenix.com

TrakCel_110_websiteThe cell therapy community is charged with the exciting and complex task of delivering novel therapeutics to patients that are safe, efficacious and affordable. Founded in 2012, TrakCel was established with the primary aim of integrating the cell therapy supply chain for autologous and allogeneic therapies to deliver safe, scalable and affordable products. Developed in partnership with major industry players, we have delivered a world-leading cell therapy supply chain solution that gives you the visibility and control required to safely scale-up and scale-out cell-based therapies. Our expertise ensures we provide our customers with solutions that meet their needs today and a technology and delivery framework that ensures we can adapt to their future needs. www.trakcel.com

  •  

    “Life Technologies has sponsored this meeting since its inception in 2006, and helped it grow into a leading, annual conference for the regenerative medicine community. Whether your goal is to gain exposure to researchers or put your name out in front of C-level executives, sponsoring this meeting has incredible value.”

    -- Alaine Maxwell, Senior District Manager, Western Canada, Life Sciences Solutions, Life Technologies, A Thermo Fisher Scientific Brand